Treatment Clinical Trials for Pancreatic Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for pancreatic cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 201-210 of 210
< Previous 1 ... 7 8 9

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 3 locations

  • Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

    Background: Gastrointestinal tumors have a molecule called CA19-9 in the tumors and blood. The agent MVT-5873 was designed to block this molecule. Researchers want to test how safe it is to give this agent to people before and after surgery to remove a tumor. They want to learn the highest dose tolerated. They want to see if getting the agent at surgery helps slow down the disease. Objective: To test the safety of giving MVT-5873 at surgery to remove cancer and see if it slows the progression of the disease. Eligibility: Adults at least 18 years old with certain cancers and certain blood CA19-9 levels Design: Participants will be screened with: - Medical history - Physical exam - Blood and heart tests - Scans - Review of normal activities - Review of tumor sample - Pregnancy test A few days before surgery, participants will get a dose of the study agent. They will get it through a small plastic tube in a vein over about 2 hours. Participants will sign a separate consent and have the surgery. A sample of the tumor and normal liver will be removed for research. For 1-2 weeks after surgery, participants will recover in intensive care then regular care at the hospital. They will be monitored and treated throughout the stay. After leaving the hospital, participants will get the study agent every week for 1 month. Then they will get it every other week for 2 months. They will repeat screening tests at study visits and at a follow-up visit. That will be about 5 weeks after the last dose.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • PEGPH20 and Pembrolizumab in Treating Patients with Hyaluronan High Metastatic Pancreatic Ductal Adenocarcinoma

    This phase II trial studies how well PEGPH20 and pembrolizumab work in treating patients with pancreatic ductal adenocarcinoma with high levels of hyaluronic acid that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PEGPH20 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving PEGPH20 in combination with pembrolizumab may work better in treating patients with metastatic pancreatic ductal adenocarcinoma than with PEGPH20 alone.
    Location: 5 locations

  • SOR-C13 in Treating Patients with Advanced Refractory Solid Tumors

    This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • iExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation

    This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Rucaparib Phosphate in Treating Patients with Advanced Pancreatic Cancer and a Known Deleterious BRCA1 / 2 or PALB2 Mutation

    This phase II trial studies how well rucaparib phosphate works in treating patients with pancreatic cancer that has spread to other parts of the body and a known deleterious BRCA1 / 2 or PALB2 mutation. Rucaparib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • CD8+ T Cell Therapy and Pembrolizumab in Treating Patients with Metastatic Gastrointestinal Tumors

    This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body. Tumor cells and blood are used to help create an adoptive T cell therapy, such as CD8+ T cell therapy, that is individually designed for a patient and may help doctors learn more about genetic changes in the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CD8+ T cell therapy and pembrolizumab may work better in treating patients with gastrointestinal tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Neoadjuvant Paricalcitol in Treating Patients with Resectable Pancreatic Cancer

    This phase Ib trial studies how well paricalcitol before primary treatment works in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as paricalcitol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Combination Chemotherapy and Stereotactic Body Radiation Therapy in Treating Patients with Resectable Pancreatic Adenocarcinoma

    This phase II trial studies how well combination chemotherapy and stereotactic body radiation therapy work in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving combination chemotherapy followed by stereotactic body radiation therapy may work better in treating patients with pancreatic cancer.
    Location: Yale University, New Haven, Connecticut

  • Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer

    This phase Ib / II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Bispecific antibody armed activated T-cells are the patient's own T cells that are coated with a bispecific antibody comprising 2 antibodies chemically joined together. These antibodies have specific targets and binding properties that may give the T cells a greater ability to seek out, attach to, and kill more cancer cells.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan


< Previous 1 ... 7 8 9